HK1200709A1 - Pharmaceutical formulations of tnf-alpha antibodies tnf- - Google Patents

Pharmaceutical formulations of tnf-alpha antibodies tnf-

Info

Publication number
HK1200709A1
HK1200709A1 HK15101176.7A HK15101176A HK1200709A1 HK 1200709 A1 HK1200709 A1 HK 1200709A1 HK 15101176 A HK15101176 A HK 15101176A HK 1200709 A1 HK1200709 A1 HK 1200709A1
Authority
HK
Hong Kong
Prior art keywords
tnf
pharmaceutical formulations
alpha antibodies
alpha
antibodies
Prior art date
Application number
HK15101176.7A
Other languages
English (en)
Chinese (zh)
Inventor
Sanjeev Kumar Mendiratta
Sanjay Bandyopadhyay
Chintan G Patel
Original Assignee
Cadila Healthcare Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48901138&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1200709(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cadila Healthcare Ltd filed Critical Cadila Healthcare Ltd
Publication of HK1200709A1 publication Critical patent/HK1200709A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
HK15101176.7A 2012-03-07 2015-02-04 Pharmaceutical formulations of tnf-alpha antibodies tnf- HK1200709A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
IN610MU2012 2012-03-07
IN1606MU2012 2012-05-30
IN3031MU2012 2012-10-17
PCT/IN2013/000129 WO2013164837A1 (fr) 2012-03-07 2013-03-05 Formulations pharmaceutiques d'anticorps anti-tnf-alpha

Publications (1)

Publication Number Publication Date
HK1200709A1 true HK1200709A1 (en) 2015-08-14

Family

ID=48901138

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15101176.7A HK1200709A1 (en) 2012-03-07 2015-02-04 Pharmaceutical formulations of tnf-alpha antibodies tnf-

Country Status (19)

Country Link
US (3) US10093728B2 (fr)
EP (3) EP3412310B1 (fr)
JP (3) JP2015509526A (fr)
KR (2) KR101730694B1 (fr)
CN (1) CN104159614A (fr)
AP (1) AP2014007922A0 (fr)
AU (1) AU2013255413C1 (fr)
BR (1) BR112014021325A2 (fr)
CA (1) CA2866692A1 (fr)
CL (1) CL2014002316A1 (fr)
EA (1) EA201491644A1 (fr)
HK (1) HK1200709A1 (fr)
MX (2) MX363700B (fr)
NZ (1) NZ629261A (fr)
PH (1) PH12014501988A1 (fr)
SG (2) SG11201405475UA (fr)
TR (1) TR201810815T4 (fr)
WO (1) WO2013164837A1 (fr)
ZA (1) ZA201406414B (fr)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040033228A1 (en) 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
WO2012149197A2 (fr) 2011-04-27 2012-11-01 Abbott Laboratories Procédé de contrôle du profil de galactosylation de protéines exprimées de manière recombinante
US10093728B2 (en) * 2012-03-07 2018-10-09 Cadila Healthcare Limited Pharmaceutical formulations of TNF-alpha antibodies
WO2013158279A1 (fr) 2012-04-20 2013-10-24 Abbvie Inc. Procédés de purification de protéines pour réduire des espèces acides
WO2013158273A1 (fr) 2012-04-20 2013-10-24 Abbvie Inc. Procédés de modulation de la distribution de variant de lysine c-terminal
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
US9249182B2 (en) 2012-05-24 2016-02-02 Abbvie, Inc. Purification of antibodies using hydrophobic interaction chromatography
JP2015519382A (ja) * 2012-06-12 2015-07-09 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 治療用抗体のための医薬処方物
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
JP6463268B2 (ja) 2012-09-07 2019-01-30 コヒラス・バイオサイエンシズ・インコーポレイテッド 安定水性アダリムマブ製剤
UA117466C2 (uk) * 2012-12-13 2018-08-10 Мерк Шарп Енд Доме Корп. СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19
WO2014143205A1 (fr) 2013-03-12 2014-09-18 Abbvie Inc. Anticorps humains qui se lient au tnf-alpha et leurs procédés de préparation
WO2014151878A2 (fr) 2013-03-14 2014-09-25 Abbvie Inc. Procédés pour la modulation des profils de glycosylation de protéines de traitements à base de protéines recombinantes au moyen de monosaccharides et d'oligosaccharides
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
WO2015051293A2 (fr) 2013-10-04 2015-04-09 Abbvie, Inc. Utilisation d'ions métalliques pour moduler les profils de glycosylation des protéines dans le cas de protéines recombinées
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
WO2015073884A2 (fr) 2013-11-15 2015-05-21 Abbvie, Inc. Compositions de protéines de liaison génétiquement glycomodifiées
CN104707146B (zh) * 2013-12-16 2019-04-16 浙江海正药业股份有限公司 一种含有阿达木单抗的药物组合物
US9732154B2 (en) 2014-02-28 2017-08-15 Janssen Biotech, Inc. Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia
IN2014MU01248A (fr) 2014-04-02 2015-10-09 Intas Pharmaceuticals Ltd
EP2946767B1 (fr) * 2014-05-23 2016-10-05 Ares Trading S.A. Composition pharmaceutique liquide
RS55548B1 (sr) 2014-05-23 2017-05-31 Ares Trading Sa Tečni farmaceutski sastav
ES2572919T3 (es) * 2014-05-23 2016-06-03 Ares Trading S.A. Composición farmacéutica líquida
US9821059B2 (en) * 2014-10-17 2017-11-21 Alteogen Inc. Composition for stabilizing protein and pharmaceutical formulation comprising the same
HUP1400510A1 (hu) 2014-10-28 2016-05-30 Richter Gedeon Nyrt Gyógyászati TNFalfa ellenes antitest készítmény
WO2016089946A1 (fr) * 2014-12-02 2016-06-09 Biogen Ma Inc. Procédés et compositions de lutte contre l'agrégation d'anticorps
EP3053572A1 (fr) * 2015-02-06 2016-08-10 Ares Trading S.A. Composition pharmaceutique liquide
WO2016162819A1 (fr) 2015-04-07 2016-10-13 Lupin Limited Composition pharmaceutique aqueuse stable d'anticorps anti-tnf alpha
US20170044265A1 (en) 2015-06-24 2017-02-16 Janssen Biotech, Inc. Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38
US11229702B1 (en) 2015-10-28 2022-01-25 Coherus Biosciences, Inc. High concentration formulations of adalimumab
LT3827845T (lt) * 2015-11-03 2022-06-10 Janssen Biotech, Inc. Poodinės anti-cd38 antikūnų kompozicijos ir jų naudojimas
EP3383435A4 (fr) * 2015-11-30 2019-07-10 Medimmune, LLC Rapports optimisés d'acides aminés et de sucres en tant que composés stabilisants amorphes dans des compositions pharmaceutiques contenant des concentrations élevées d'agents thérapeutiques à base de protéine
AU2016380988B2 (en) * 2015-12-30 2022-07-21 Genentech, Inc. Formulations with reduced degradation of polysorbate
JP6738608B2 (ja) * 2016-01-22 2020-08-12 田中貴金属工業株式会社 クロマトグラフ媒体
GB201604124D0 (en) * 2016-03-10 2016-04-27 Ucb Biopharma Sprl Pharmaceutical formulation
US11071782B2 (en) 2016-04-20 2021-07-27 Coherus Biosciences, Inc. Method of filling a container with no headspace
MA45562B1 (fr) * 2016-06-30 2024-05-31 Celltrion Inc Préparation pharmaceutique liquide stable
FR3054444A1 (fr) * 2016-07-29 2018-02-02 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Composition orale d'anticorps anti-tnf alpha
US11692027B2 (en) 2016-09-28 2023-07-04 Board Of Regents, The University Of Texas System Antibody and protein therapeutic formulations and uses thereof
EP3533441A4 (fr) * 2016-10-28 2019-12-04 Celltrion Inc. Formulation pharmaceutique stable
US10940185B2 (en) 2016-12-28 2021-03-09 Jcr Pharmaceuticals Co., Ltd. Lyophilized preparation
RU2665966C2 (ru) * 2016-12-30 2018-09-05 Закрытое Акционерное Общество "Биокад" Водная фармацевтическая композиция рекомбинантного моноклонального антитела к ФНОα
JOP20190162A1 (ar) * 2016-12-30 2019-06-27 Biocad Joint Stock Co تركيبة صيدلانية مائية من جسم مضاد لـ tnf? أحادي النسيلة معاود الارتباط الجيني
WO2018131893A1 (fr) * 2017-01-11 2018-07-19 ㈜셀트리온 Formule liquide stable
US11608357B2 (en) 2018-08-28 2023-03-21 Arecor Limited Stabilized antibody protein solutions
EP3372242A1 (fr) 2017-03-06 2018-09-12 Ares Trading S.A. Composition pharmaceutique liquide
EP3372241A1 (fr) 2017-03-06 2018-09-12 Ares Trading S.A. Composition pharmaceutique liquide
JP7109849B2 (ja) * 2017-03-16 2022-08-01 エルジー・ケム・リミテッド 抗ＴＮＦα抗体の液状製剤
CN108686204A (zh) * 2017-04-07 2018-10-23 浙江海正药业股份有限公司 包含组氨酸缓冲体系的英夫利西单抗组合物
CN108686205B (zh) * 2017-04-07 2021-12-10 海正生物制药有限公司 英夫利西单抗冻干制剂
RU2019138507A (ru) 2017-05-02 2021-06-02 Мерк Шарп И Доум Корп. Составы антител против lag3 и совместные составы антител против lag3 и антител против pd-1
JOP20190260A1 (ar) 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
KR20200038507A (ko) * 2017-08-08 2020-04-13 체에스엘 베링 아게 헤모펙신 제형
WO2019089832A1 (fr) 2017-10-31 2019-05-09 Janssen Biotech, Inc. Méthodes de traitement du myélome multiple à haut risque
CN110151988A (zh) * 2018-02-11 2019-08-23 百奥泰生物制药股份有限公司 一种靶向治疗TNF-α相关疾病的人抗体制剂
CN110302377B (zh) * 2018-02-11 2020-04-17 百奥泰生物制药股份有限公司 一种靶向治疗TNF-α相关疾病的人抗体制剂
MA55033A (fr) 2019-02-18 2021-12-29 Lilly Co Eli Formulation d'anticorps thérapeutique
US20220042977A1 (en) * 2020-08-04 2022-02-10 ProStabilis, Inc. Protein Solubility Screening Kits and Their Use
KR20230054395A (ko) * 2020-08-20 2023-04-24 모멘타 파머슈티컬스 인코포레이티드 시알릴화된 당단백질
WO2022111547A1 (fr) * 2020-11-24 2022-06-02 The University Of Hong Kong Formulations de poudre inhalées pour l'administration d'anticorps par voie respiratoire
AU2022348349A1 (en) * 2021-09-16 2024-05-02 Aprogen Inc. PHARMACEUTICAL COMPOSITION CONTAINING ANTI-TNFα ANTIBODY
CN118225545A (zh) * 2024-05-23 2024-06-21 江西赛基生物技术有限公司 一种重组人TNF-α蛋白冻干小球及其制备方法和应用

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US609382A (en) 1898-08-16 Cotton-chopper
US6090382A (en) 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
CA2243459C (fr) 1996-02-09 2002-09-17 Basf Aktiengesellschaft Anticorps humains se fixant au facteur necrosant des tumeurs de type .alpha.
EP0852951A1 (fr) * 1996-11-19 1998-07-15 Roche Diagnostics GmbH Compositions pharmaceutiques stables, lyophilisées d'anticorps monoclonaux ou polyclonaux
CA2454587C (fr) * 2001-07-25 2012-11-13 Protein Design Labs, Inc. Formulation pharmaceutique lyophilisee stable d'anticorps igg
MXPA04008215A (es) * 2002-02-27 2004-11-26 Immunex Corp Formulacion polipeptidica.
US20040033228A1 (en) * 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
AU2003293543A1 (en) * 2002-12-13 2004-07-09 Abgenix, Inc. System and method for stabilizing antibodies with histidine
AU2007212147A1 (en) * 2006-02-03 2007-08-16 Medimmune, Llc Protein formulations
TWI527603B (zh) * 2006-06-30 2016-04-01 艾伯維生物技術有限責任公司 自動注射裝置
EP2131834A2 (fr) * 2007-04-11 2009-12-16 Alcon Research, Ltd. Utilisation d'un inhibiteur de tnfa et d'une anti-histamine pour traiter la rhinite allergique et la conjonctivite allergique
PE20091174A1 (es) 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd Formulacion liquida con contenido de alta concentracion de anticuerpo
EP4104821A1 (fr) * 2008-10-29 2022-12-21 Ablynx N.V. Formulations de molécules de liaison d'antigène monodomaines
PE20120169A1 (es) * 2008-11-17 2012-02-29 Genentech Inc Metodo y formulacion para reducir la agregacion de una macromolecula bajo condiciones fisiologicas
JP2012526121A (ja) 2009-05-04 2012-10-25 アボツト・バイオテクノロジー・リミテツド ヒト抗ｔｎｆアルファ抗体の安定した高蛋白質濃度製剤
KR20120130757A (ko) * 2010-02-26 2012-12-03 노보 노르디스크 에이/에스 안정한 항체 함유 조성물
ES2910305T3 (es) * 2010-08-19 2022-05-12 Zoetis Belgium S A Anticuerpos anti-NGF y su uso
EP2471554A1 (fr) 2010-12-28 2012-07-04 Hexal AG Formulation pharmaceutique comprenant un médicament biopharmaceutique
GB201112429D0 (en) 2011-07-19 2011-08-31 Glaxo Group Ltd Antigen-binding proteins with increased FcRn binding
US10093728B2 (en) * 2012-03-07 2018-10-09 Cadila Healthcare Limited Pharmaceutical formulations of TNF-alpha antibodies
JP2015519382A (ja) 2012-06-12 2015-07-09 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 治療用抗体のための医薬処方物
JP6463268B2 (ja) 2012-09-07 2019-01-30 コヒラス・バイオサイエンシズ・インコーポレイテッド 安定水性アダリムマブ製剤

Also Published As

Publication number Publication date
KR101730694B1 (ko) 2017-04-27
EP3412310B1 (fr) 2022-09-07
ZA201406414B (en) 2016-08-31
KR20160105535A (ko) 2016-09-06
EP2822591A1 (fr) 2015-01-14
CN104159614A (zh) 2014-11-19
KR20140134689A (ko) 2014-11-24
AU2013255413B2 (en) 2015-11-05
EP2822591B1 (fr) 2018-05-02
CL2014002316A1 (es) 2015-02-27
EP3912639A1 (fr) 2021-11-24
EP3412310A1 (fr) 2018-12-12
JP2015509526A (ja) 2015-03-30
WO2013164837A1 (fr) 2013-11-07
PH12014501988B1 (en) 2014-11-24
AU2013255413A1 (en) 2014-09-25
NZ629261A (en) 2017-08-25
US20230047111A1 (en) 2023-02-16
US20190071496A1 (en) 2019-03-07
MX363700B (es) 2019-03-29
AP2014007922A0 (en) 2014-09-30
TR201810815T4 (tr) 2018-08-27
US10093728B2 (en) 2018-10-09
PH12014501988A1 (en) 2014-11-24
SG11201405475UA (en) 2014-10-30
AU2013255413C1 (en) 2016-03-24
EA201491644A1 (ru) 2014-12-30
BR112014021325A2 (pt) 2017-08-22
JP2018162295A (ja) 2018-10-18
US20150071936A1 (en) 2015-03-12
JP6416841B2 (ja) 2018-10-31
MX2019003716A (es) 2019-09-04
SG10201609982PA (en) 2017-01-27
JP2017019855A (ja) 2017-01-26
MX2014010776A (es) 2014-10-14
CA2866692A1 (fr) 2013-07-11

Similar Documents

Publication Publication Date Title
HK1200709A1 (en) Pharmaceutical formulations of tnf-alpha antibodies tnf-
HK1255336A1 (zh) 藥物製劑及其製備方法
HK1212701A1 (zh) 恩雜魯胺製劑
HK1203812A1 (en) Novel pharmaceutical formulations
EP2864361A4 (fr) Régime posologique de composés de fusion
ZA201504408B (en) Solution formulations of engineered anti-il-23p19 antibodies
HRP20180567T1 (hr) Farmaceutski pripravak omeprazola
IL236465B (en) Pharmaceutical composition for delayed release of active substances
HK1209339A1 (en) Pharmaceutical formulations
IL227905A0 (en) Toroidal pharmaceutical compositions
GB201211406D0 (en) Pharmaceutical formulations
GB201211403D0 (en) Pharmaceutical formulations